Making better drugs: Decision gates in non-clinical drug development

Nature Reviews Drug Discovery

Volumn 2, Issue 7, 2003, Pages 542-553

  Pritchard, J Fred ^a   Jurima Romet, Malle ^a   Reimer, Mark L J ^a   Mortimer, Elisabeth ^b   Rolfe, Brenda ^a   Cayen, Mitchell N ^c  

^a MDS Inc   (Canada)

^b MDS Pharma Services   (France)

^c Cayen Pharmaceutical Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FEXOFENADINE; INSULIN SENSITIZING AGENT; ION TRANSPORT AFFECTING AGENT; NEW DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RAGAGLITAZAR; TERFENADINE; TRASTUZUMAB; UNCLASSIFIED DRUG;

CARCINOGENICITY; DECISION MAKING; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE TRANSPORT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TORSADE DES POINTES; TOXICITY TESTING; ABSORPTION; ANIMAL; TOXICOLOGY;

ABSORPTION; ANIMALS; DRUG DESIGN; HUMANS; TOXICOLOGY;

EID: 0038004738     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1131     Document Type: Review

References (78)

1. Guidance for Industry: S7A Safety Pharmacology Studies for Human Pharmaceuticals. US Food and Drug Administration, July 2001 http://www.fda.gov/cder/4461fnl.pdf (2001).
2. ICH Final Draft Guidance for Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: Proposal for revision. 8 November 2000.
3. Pharmaceutical Research and Manufacturers of America (PhRMA), Phrma FAX of the Week, May 2, 2003, R&D Process: Long, Expensive, Risky Road.
4. Lin, J. H. & Lu, A. Y. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49, 403-449 (1997).
5. Gunaratna, C. Drug metabolism & pharmacokinetics in drug discovery: a primer for bioanalytical chemists, part I. Curr. Sep. 19, 17-23 (2000).
6. Kapur, R. Smarter lead optimization enabled. Drug Discov. Dev. 61. (1999).
7. Lead optimization strategies. Genet. Eng. News 19, 16 (1999).
8. Benet, L. Z. & Hoener, B. A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71, 115-121 (2002).
9. Artursson, P. Epithelial transport of drugs in cell culture I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79, 476-482 (1990).
10. Irvine, J. D. et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci. 88, 28-33 (1997).
11. Inui, K.-I., Yamamoto, M. & Saito, H. Transepithelial transport of oral cephalosporins by monolayers of intestinal epitheial cell line Caco-2: specific transport systems in apical and basolateral membranes. J. Pharmacol. Exp. Ther. 261, 195-201 (1992).
12. Lu, S., Guttendorf, R. J. & Stewart, B. H. The mechanism of cefdinir transport in CaCO-2 cells. Pharm. Res. 11, S-258 (1994).
13. Artursson, P. & Borchardt, R. T. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14, 1655-1658 (1997).
14. Balkovetz, D. F. Hepatocyte growth factor and Madin-Darby canine kidney cells: in vitro models of epithelial cell movement and morphogenesis. Microsc. Res. Tech. 43, 456-463 (1998).
15. Kansey, M. et al. Physiochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41, 1007-1010 (2001).
16. Sugano, K., Hamada, H., Machida, M. & Ushio, H. High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J. Biomol. Screen. 16, 189-196 (2001).
17. Baillie, T. A. et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196 (2002).
18. Hawksworth, G. M. Advantages and disadvantages of using human cells for pharmacological and toxicological studies. Hum. Exp. Tox. 13, 568-573 (1994).
19. Roberts, S. A. Drug metabolism and pharmacokenetics in drug discovery. Curr. Opin. Drug Discov. Devel. 6, 66-80 (2003).
20. de Groene, E. M. et al. Development of human cytochrome P450-expressing cell lines: application in mutagenicity testing of ochratoxin A. Cancer Res. 56, 299-303 (1996).
21. de Greene, E. M. in Cytochrome P450 Protocols Methods in Molecular Biology (eds Shephard, E. A. & Phillips, E. A.) 219-226 (1998)
22. Li, A. P. et al. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem. Biol. Interact. 121, 117-123 (1999).
23. Li, A. P. et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121, 17-35 (1999).
24. White, R. E. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu. Rev. Pharmacol. Toxicol. 40, 133-157 (2000).
25. Roberts, S. A. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 31, 557-589 (2001).
26. Eichelbaum, M. Polymorphic drug oxidation in humans. Fed Proc. 43, 2298-2392 (1984).
27. Dayer, P. et al. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) - increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers. Biochem. Biophys. Res. Commun. 125, 374-380 (1984).
28. Pettipher, R. The role of genomics in the development of new and improved therapies: An appreciation of the importance of genetic diversity will have a profound impact on how drugs are discovered, developed and prescribed. Innov. Pharm. Technol. 62-67 (2000).
29. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 27, 383-391 (2001).
30. Guengerich, F. P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17 (1999).
31. Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (1997) Food and Drug Administration: http://www.fda.gov/cder/guidance/clin3.pdf (1997)
32. Clancy, C. E. & Rudy, Y., Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature 400, 566-569 (1999).
33. Bian, J., Cui, J. & McDonald, T. V. HERG K(+) channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate. Circ. Res. 89, 1168-1176 (2001).
34. Zhou, Z., Gong, Q., Epstein, M. L. January, C. T. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J. Biol. Chem. 273, 21061-21066 (1998).
35. Ulrich, R. & Friend, S. H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nature Rev. Drug Discov. 1, 85-88 (2002).
36. Schmidt, C. W. Toxicogenomics: an emerging discipline. Environ. Health Perspect. 110, A750-A755 (2002).
37. Thayer, A. M. Genomics moves on. Chem. Eng. News 80, 25-36 (2002).
38. Therapeutic Products Directorate Guidance: Drug-Drug Interaction Studies: In Vivo and In Vitro. Health Canada Website: http://www.hc-sc.gc.ca (2000).
39. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labelling. US Food and Drug Administration http://www.fda.gov/cder/guidance/2635.pdf (1999).
40. Huang, S.-M. et al. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: Study design and data analysis issues. J. Clin. Pharmacol. 39, 1006-1014 (1999).
41. Guidance for Industry: Good Laboratory Practice for Nonclinical Laboratory Studies (21 CFR Part 58) US Food and Drug Administration. http://www.fda.goc/cder
42. Eddershaw, P. J., Beresford, A. P. & Bayliss, M K. ADME/PK as part of a rational approach to drug discovery. Drug Discov. Today 5, 409-414 (2000).
43. Guidance for Industry: Good Laboratory Practice for Nonclinical Laboratory Studies (21 CFR Part 58) Food and Drug Administration Homepage. http://www.fda.goc/cder
44. Wilding, I. Injecting innovation into the drug development process. Scripps Magazine 15-16, October (2002).
45. Bayliss, M. K. & Frick, L. W. High-throughput pharmacokinetics: Cassette doisng. Curr. Opin. Drug Discov. Devel. 2, 20-25 (1999).
46. Cayen, M. N. Considerations in the design of toxicokinetic programs. Tox. Path. 23, 148-157 (1995).
47. Guideline for Industry: Detection of Toxicity to Reproduction for Medicinal Products. Food and Drug Administration.
48. Gonzalez, F. J. Overview of experimental approaches for study of drug metabolism and drug-drug interactions. Adv. Pharmacol. 43, 255-277 (1997).
49. Guideline for Industry: Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies. US Food and Drug Administration http://www.fda.gov/cder/guidance/ichs3b.pdf (1995)
50. Guidance for Industry: S4ADuration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Testing). US Food and Drug Adminsitration. (1999).
51. Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs, Issued October 2002, Food and Drug Administration. http://www.fda.gov/cder/guidance/4945fnl.doc (2002)
52. ICH Draft Consensus Guideline: Safety Pharmacology Studies For Assessing The Potential For Delayed Ventricular Repolarization (Qt Interval Prolongation) By Human Pharmaceuticals, February 2002.
53. Beckwith-Hall, B. M. et al. Nuclear magnetic spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem. Res. Tox. 11, 260-272 (1998).
54. 19F NMR and directly coupled HPLC-NMR-MS investigations into the metabolism of 2-bromo-4-trifluoromethylaniline in the rat: a urinary excretion balance study without the use of radiolabelling. Xenobiotica 28, 373-388 (1998).
55. Cherry, S. R. et al. MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans. Nucl. Sci. 44, 1161-1166 (1997).
56. Paans, A. M. J. & Vaalburg, W. Positron emission tomography in drug development and drug evaluation. Curr. Pharm. Des. 6, 1583-1591 (2000).
57. Benet, L. Z. & Hoener, B. A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71, 115-121 (2002).
58. Spahn Langguth, H. et al. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as a model compound. Int. J. Clin. Pharmacol. Ther. 36, 16-24 (1998).
59. Ramaswamy, M. et al. Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. J. Pharm. Pharm. Sci. 5, 29-38 (2002).
60. Tucker, G. T, Houston, J. B. & Huang, S.-M., Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin. Pharmacol. Ther. 70, 103-114 (2001).
61. Moore, L. B. et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Aced. Sci. USA 97, 7500-7502 (2000).
62. Li, A. P. Primary hepatocyte cultures as an in vitro experimental system for the evaluation of pharmacokinetic drug-drug interactions. Adv. Pharmacol. 43, 103-130 (1997).
63. Lehmann, J. M. et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023 (1998).
64. Goodwin, B., Hodgson, E. & Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339 (1999).
65. Ogg, M. S. et al. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 29, 269-279 (1999).
66. Luo, G. et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and Cyp3A4 expression in human hepatoyctes. Drug Metab. Dispos. 30, 795-804 (2002).
67. Baillie, T. A. et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196 (2002).
68. Guideline for Industry: The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals, ICHS1A. US Food and Drug Administration, http://www.fda.gov/cder/guidance/ichs1a.pdf (1996).
69. Guidance for Industry: S1B Testing for Carcinogenicity of Pharmaceuticals. US Food and Drug Administration. http://www.fda.gov/cder/guidance/1854fnl.pdf (1997).
70. Press Release, Novo Nordisk suspends the clinical development of ragaglitazar (NN622), Bagsvaerd, Denmark (July 22, 2002).
71. Press Release, January 30, 2003, Pharmaceutical Research and Manufacturers of America (PhRMA), Pharmceutical Companies Receive FDA Approval for 26 NME and Biologics, 63 Other New Medicines and 172 New Uses for Medicines in 2002.
72. Ackerman, B. L., Murphy, A. T. & Berna, M. J. The resurgence of column switching techniques to facilitate rapid LC/MS/MS based bioanalysis in drug discovery. Amer. Pharm. Rev. 5, 54-63 (2002).
73. Clarke, N. J., Rindgen, D., Korfmacher, W. A. & Cox, K. A. Systematic LC/MS metabolite identification in drug discovery. Anal. Chem. 73, 430A-439A (2001).
74. March, R. E. An introduction to quadrupole ion trap mass spectrometry. J. Mass Spectrom. 32, 351-369 (1997).
75. Chernushevich, I. V., Loboda A. V. & Thomson, B. A. An introduction to quadrupole-time-of-flight mass spectrometry. J. Mass Spectrom. 36, 849-865 (2001).
76. Albert, K. Liquid chromatography - nuclear magnetic resonance spectroscopy. J. Chromatogr. A. 856, 199-211 (1999).
77. Hagar, J. W. A new linear ion trap mass spectrometer Rapid Commun. Mass Spectrom. 16, 512-526 (2002).
78. Marshall, A. G., Hendrickson, C. L. & Shi, D.-H. S. Scaling MIS plateaus with FTICR MS. Anal. Chem. 74, 252A-259A (2002).